Human Genome Sciences, Inc. v. Amgen, Inc.

552 F. Supp. 2d 466, 2008 U.S. Dist. LEXIS 38464, 2008 WL 2018439
District Court, D. Delaware·Decided May 9, 2008·No. Civ. 07-780-SLR·Published·Cited by 3 cases

Opinion

MEMORANDUM OPINION

SUE L. ROBINSON, District Judge.

I. INTRODUCTION

Plaintiff Human Genome Sciences, Inc. (“HGS”) filed the present action against Immunex Corp. (“Immunex”) and Amgen, Inc. (collectively, “defendants”) on November 30, 2007, seeking review of a Decision on Motions entered on July 26, 2007 and Final Judgment entered November 20, 2007 by the Board of Patent Appeals and Interferences (the “Board”) of the United States Patent and Trademark Office (“PTO”) in Interference No. 105,240 (“the '240 interference”). (D.I.l) Defendants filed a motion to dismiss on January 16, 2008. (D.I.8) For the reasons that follow, the court grants defendants’ motion.

II. BACKGROUND

A. Procedural Background

The American patent law system recognizes the first to invent, rather than the first to file. Consequently, there exists a complicated administrative process by which the PTO has jurisdiction in the first instance to determine priority of invention. The process, an “interference,” has been described as “tortuous,” “arcane,” “highly specialized,” and “virtually incomprehensible to the uninitiated.” Patents and the Federal Circuit, Fourth Edition, Robert L. Harmon, § 15.2 at 724-25 (1999).

At the beginning of an interference, the party that is first to file an application describing and enabling the “count” declared in the interference is designated the “Senior Party,” and the second the “Junior Party”; the Junior Party bears the burden of proof during the priority phase. 37 C.F.R. § 41.207(a). “A common two-party interference before the PTO is an administrative proceeding expected to be concluded in 24 months.” General Instrument Corp. v. Scientific-Atlanta, Inc., 995 F.2d 209, 211 (Fed.Cir.1993). The first phase in an interference is the preliminary motions phase. Because a party may not raise any issue at a final hearing that was not, but could have been, raised by a preliminary motion, “the preliminary motions which a party files or does not file ... can have far reaching consequences for both the outcome of the interference and subsequent ex parte prosecution.” Id. at 212. Consequently, the Federal Circuit has advised that a party’s preliminary motions take into account its “long-range strategy with respect to ... priority and patentability issues in the interference.” Id. (alteration in original). Preliminary motions generally are filed to redefine the scope of a contested case, to change the benefit date accorded for the contested subject matter, or for judgment in the contested case. 37 C.F.R. § 41.121(a)(1). “To be sufficient, a motion must provide a showing, supported with appropriate evidence, such that, if *468 unrebutted, it would justify the. relief sought. The burden of proof is on the movant.” 37 C.F.R. § 41.208(b).

“If the examiner-in-chiefs rulings on the preliminary motions do not terminate the interference,” General Instrument, 995 F.2d at 212, the interference moves into the priority phase, wherein the Board receives testimony and evidence and decides the ultimate issue of priority of inventor-ship. A party dissatisfied with the Board’s final decision may request reconsideration of that decision, or it may seek judicial review. With respect to the latter course of action, a party may proceed directly to the Federal Circuit for review based on the record before the Board, or it may proceed to a district court for a “hybrid appeal/trial de novo proceeding in which the PTO record is admitted on motion of either party, but it may be supplemented by further testimony.” Id. at 212; 35 U.S.C. §§ 141-144, 146. “District court review of an interference proceeding under section 146 is an equitable remedy of long standing.” General Instrument, 995 F.2d at 214. As a proceeding sounding in equity, “the district court may, in appropriate circumstances, exercise its discretion and admit testimony on issues even though they were not raised before the Board.” Id. Generally, however, for an issue to qualify for evidentiary review in a § 146 proceeding, “more is required than passing reference to the subject during the course of the interference proceeding.” Id.

B. Factual Background

HGS is the owner by assignment of the invention disclosed in U.S. Patent No. 6,872,568 (“the '568 patent”). The '568 patent, entitled “Death domain containing receptor 5 antibodies,” issued March 29, 2005 to inventors Jian Ni (“Ni”) et al., (D.I. ¶ at ¶ 10) The '568 patent was filed on May 4, 2000 as a continuation-in-part of U.S. Patent Application No. 09/042,583, filed March 17, 1998, which claims priority to two provisional applications, U.S. Patent Application Nos. 06/040,846 and 60/054,021, filed March 17, 1997 and July 29, 1997, respectively. Defendants are the owner of U.S. Patent Application No. 09/378,045 (“the '045 application), filed August 20, 1999 and entitled “Receptor that binds TRAIL.” (Id. at ¶ 11)

The Board declared the '240 interference between the '568 patent and the '045 application, with claims 1-6, 8-19, 21-32, 34^5 and 47-52 of the '568 patent being designated as corresponding to the count of the '240 interference, (Id. at ¶ 13) Defendant Immunex was declared the Senior Party and was presumed to be the first to invent the subject matter of the count. Both parties moved to be accorded earlier benefit dates based upon earlier-filed applications. On or about July 26, 2007, the Board issued its Decision on Motions which held, inter alia, that Immunex was entitled to the benefit of an application filed on February 13, 1997, whereas HGS was entitled to the benefit date of May 4, 2000, the date the application issuing as the '568 patent was filed. (D.I. 10, ex. C at 13-15, 54) In other words, the Board did not afford HGS the benefit of any of its earlier filed applications in the chain because HGS did not sufficiently connect the disclosure of the '568 patent, filed as a continuation-in-part application, to that of the applications preceding it. More specifically, in its July 26, 2007 decision, the Board explained that

[i]t is not the job of the Board to pour through hundreds of pages of text and sheets of drawings to find disclosure alleged to be “at least the same disclosure as is found in the March 17 and July 29, 1997 priority applications.” See United States v. Dunkel, 927 F.2d 955, 956 (7th Cir.1991) (“[jjudges are not like pigs hunting for truffles buried in *469 briefs”). It is not the fact finder’s burden to search through lengthy technology-intense documents for possible evidence which may support Ni’s “at least the same reasons.”

(Id., ex.

Free access — add to your briefcase to read the full text and ask questions with AI

Human Genome Sciences, Inc. v. Amgen, Inc., 552 F. Supp. 2d 466, 2008 U.S. Dist. LEXIS 38464, 2008 WL 2018439 (D. Del. 2008).

552 F. Supp. 2d 466 (Human Genome Sciences, Inc. v. Amgen, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Loughlin v. Ling
684 F.3d 1289 (Federal Circuit, 2012)
Abbott GmbH & Co. v. Centocor Ortho Biotech, Inc.
870 F. Supp. 2d 206 (D. Massachusetts, 2012)
Human Genome Sciences, Inc. v. Genentech, Inc.
589 F. Supp. 2d 512 (D. Delaware, 2008)